Could starting with fewer drugs be just as effective for multiple myeloma?
NCT ID NCT01919086
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new way to treat multiple myeloma by starting with just two drugs (bortezomib and dexamethasone) and adding a third (lenalidomide) only if the disease wasn't well controlled. The goal was to see if this step-by-step approach could achieve the same good results as giving all three drugs at once, but with fewer side effects. Thirty adults with newly diagnosed multiple myeloma took part in this phase 2 trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bortezomib, dexamethasone, and lenalidomide
What this could lead to
If successful, this approach could show that starting with fewer drugs and adding more only when needed works just as well as using all three from the start, with fewer side effects.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The sequential approach might not control the disease as well as the standard three-drug combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hartford Healthcare Cancer Institute @ Hartford Hospital
Hartford, Connecticut, 06102, United States
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States